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Abstract
Purpose A breast cancer diagnosis has a substantial economic impact. Study aims were to evaluate for inter-individual differ-
ences in cancer’s level of interference with employment and identify phenotypic and symptom characteristics associated with
higher levels of interference.
Methods Patients (n = 387) were enrolled prior to breast cancer surgery and followed for 12 months. Interference with employ-
ment was measured using a 0 (no problem) to 10 (severe problem) numeric rating scale. Hierarchical linear modeling (HLM) was
used to evaluate for inter-individual differences in trajectories of employment interference and characteristics associated with
employment interference at enrollment and over 12 months.
Results Patients’ mean age was 55.0 (±11.7) years and the majority underwent breast conservation surgery (80.6%). Mean
employment interference score was 3.2 (±3.7). Unconditional model for employment interference demonstrated a decreasing
linear trend (−.076/month). Younger age, lower income, higher pain intensity, and having an axillary lymph node dissection were
associated with higher pre-surgical interference scores. Having a sentinel lymph node biopsy was associated with ongoing
employment interference scores. Higher sleep disturbance scores were associated with both initial and ongoing employment
interference scores. Receipt of chemotherapy, use of complementary or alternative therapies, and re-excision or mastectomy
following surgery were significant time varying covariates.
Conclusion This study is the first to use HLM to describe inter-individual differences in the trajectories of cancer’s interference
with employment and associated factors prior to and for 12 months following breast cancer surgery. Patients with the identified
risk factors warrant ongoing assessments of employment interference and appropriate referrals.
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Introduction
In the United States, an estimated 268,600 new cases of
female breast cancer will be diagnosed in 2019 [1]. This
cancer diagnosis and its treatment can have significant
short- and long term impacts on patients’ employment
[2]. For example, in one study [3], compared to healthy
controls, breast cancer patients were significantly less
likely to be employed six months after diagnosis, and
among those who continued to work, they worked fewer
hours. Cancer’s interference with employment is substan-
tial and often extends beyond treatment and into survivor-
ship regardless of whether the patient eventually returns
to work [2].
Depending on an individual’s personal situation and
the treatments she receives, breast cancer patients report
absenteeism from work, reduced work ability, limited
work performance and career progression, and at times,
voluntary termination of employment [2, 4]. This interfer-
ence with employment is associated with a higher finan-
cial burden [5]. In monetary terms, according to a recent
analysis of the National Health Interview Survey conduct-
ed in the United States [6], for women with breast cancer,
the foregone annual earnings were estimated at $2293 per
capita for women aged 18–44 years and $1407 per capita
for women aged 45–64 years.
A number of factors are associated with changes in
employment after a breast cancer diagnosis. Patient fac-
tors such as lower levels of education and physical and
mental health, as well as lack of support from col-
leagues and supervisor contributed to early retirement
and non-employment among breast cancer patients [7,
8]. In terms of symptom burden, higher levels of pain
[9], anxiety [10–14], fatigue [10–14], depression
[10–14], and cognitive dysfunction [11, 14, 15] were
associated with higher employment interference after
breast cancer treatment. Across these studies, employ-
ment interference was categorized as whether or not
patients returned to work, retired, or reduced the num-
ber of hours worked after their cancer treatment [9–15].
One limitation of these categorizations is that they did
not discriminate between whether these employment
changes were due to the breast cancer diagnosis itself
or the receipt of single (e.g., surgery alone) or multi-
modal (e.g., surgery and radiation therapy) treatments.
In addition, these studies did not evaluate for changes
over time in employment interference and associated
predictors. Therefore, the purposes of this study were
to evaluate for inter-individual differences in cancer’s
level of interference with employment among women
with breast cancer from prior to through 12 months af-
ter surgery and identify phenotypic and symptom char-
acteristics associated with higher levels of interference.
Methods
Patients and settings
This descriptive, longitudinal analysis is part of a larger
National Cancer Institute funded study that evaluated for neu-
ropathic pain and lymphedema in women who underwent
breast cancer surgery [16]. Patients were recruited from
Breast Care Centers located in a Comprehensive Cancer
Center, two public hospitals, and four community practices.
Patients were eligible to participate if they were women >-
18 years of age who would undergo breast cancer surgery on
one breast; were able to read, write, and understand English;
agreed to participate; and gave written informed consent.
Patients were excluded if they were having breast cancer sur-
gery on both breasts and/or had distant metastases at the time
of diagnosis.
Instruments
At enrollment, a demographic questionnaire obtained infor-
mation on age, gender, marital status, level of education, eth-
nicity, employment status, and annual household income.
Functional status was assessed using the Karnofsky
Performance Status (KPS) scale [17]. Level of comorbidity
was assess using the Self-Administered Comorbidity
Questionnaire (SCQ). Possible scores can range from 0 to 39
[18].
For this study, interference with employment was assessed
using a single item from the Quality of Life Scale-Patient
Version (QOL-PV) [19], namely, “To what degree has your
illness or treatment interfered with your employment?”.
Patients were asked to rate this item using a 0 (no problem)
to 10 (severe problem) numeric rating scale (NRS).
The Spielberger State-Trait Anxiety Inventories (STAI-S,
STAI-T) were used to assess an individual’s transitory emo-
tional response to a stressful situation (i.e., right now), as well
as his/her predisposition to anxiety, respectively. Scores for
each scale are summed and can range from 20 to 80. A higher
score indicates greater anxiety. Cut off scores of >31.8
and >32.2 indicate high levels of trait and state anxiety, re-
spectively [20]. In this study, Cronbach’s alphas for the STAI-
T and STAI-S were .88 and .95, respectively.
The 20-item Center for Epidemiological Studies
Depression Scale (CES-D) was used to evaluate the major
symptoms in the clinical syndrome of depression. Scores
can range from 0 to 60, with scores of >16 indicating the need
for individuals to seek clinical evaluation [21]. In this study, its
Cronbach’s alpha was 0.90.
The 18-item Lee Fatigue Scale (LFS) was used to assess
physical fatigue and energy [22]. Each itemwas rated on a 0 to
10 NRS. Total fatigue and energy scores were calculated as
the mean of the 13 fatigue and the 5 energy items. Higher
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scores indicate greater fatigue severity and higher levels of
energy. Patients were asked to rate each item based on how
they felt “right now”. Cut-off scores of >4.4 and <4.8 indicate
high levels of fatigue and low levels of energy respectively
[23]. In this study, Cronbach’s alphas for fatigue and energy
scales were .96 and .93, respectively.
The 16-item Attentional Function Index (AFI) was used to
measure attentional function. Each item was rated on a 0 to 10
NRS. A higher mean score indicates greater capacity to direct
attention. Scores are grouped into categories of attentional
function (i.e., <5.0 low function, 5.0 to 7.5 moderate function,
>7.5 high function) [24]. In this study, its Cronbach’s alpha
was .95.
The 21-item General Sleep Disturbance Scale (GSDS) was
used to assess the quality of sleep in the past week. Each item
was rated on a 0 (never) to 7 (everyday) NRS. The GSDS total
score is the sum of 21 items that can range from 0 (no distur-
bance) to 147 (extreme sleep disturbance). A GSDS total
score of >43 indicates a significant level of sleep disturbance
[25]. In this study, its Cronbach’s alpha was .86.
The occurrence of breast pain prior to surgery was deter-
mined by asking the question “Are you experiencing pain in
your affected breast?” If women responded yes, they rated
their average and worst pain using a 0 (no pain) to 10 (worst
imaginable pain) NRS.
Study procedures
The study was approved by the Committee on Human
Research at the University of California, San Francisco and
by the Institutional Review Board at each of the study sites.
During the patient’s preoperative visit, a clinical staff member
explained the study to the patient and determined her willing-
ness to participate. The staff member introduced women who
were willing to participate to the research nurse. The research
nurse met with the women, determined eligibility, and obtain-
ed written informed consent prior to surgery. After obtaining
consent, patients completed the enrollment questionnaires an
average of four days prior to surgery and at one, two, three,
four, five, six, eight, ten, and twelve months after surgery. The
research nurse met with the patients at the Clinical Research
Center or in their homes. Patients’ medical records were
reviewed for disease and treatment information.
Data analysis
Descriptive statistics and frequency distributions were com-
puted for sample characteristics and symptom severity scores
using SPSS version 23 (IBM, Armonk, NY). With the excep-
tion of the employment interference item from the QOL-PV
and the time varying covariates (i.e., radiation therapy, che-
motherapy, hormonal therapy, complementary/alternative
therapy, breast reconstruction, and re-excision or mastectomy
of the affected breast) which were assessed prior to surgery
and at 1, 2, 3, 4, 5, 6, 8, 10, and 12months after surgery), all of
the demographic, clinical, and symptom characteristics that
were evaluated as predictors in the hierarchical linear model-
ing (HLM) analysis were assessed prior to surgery.
Hierarchical linear modeling, based on full maximum like-
lihood estimation, was done using Stata/SE (StataCorp, 2017).
In brief, the HLM analysis was done to evaluate for changes
over time in ratings of “To what degree has your illness or
treatment interfered with your employment?”. First, intra-
individual variability in employment interference over time
was examined and the best fitting unconditional model was
identified (no covariates in the model except time). Models
were compared to identify the best fitting change trajectory
(i.e., only linear or linear and quadratic effects) and the best
fitting covariance structure for the random effects at level 2
(random intercepts only; or random intercepts, random slopes,
and the covariance between intercepts and slopes – an “un-
structured covariance matrix”). The criteria used to evaluate
for “best fit” were a combination of significant vs non-
significant fixed effects and the model with the smallest
Akaike’s Information Criterion (AIC) [26]. From these analy-
ses, the best fitting unconditional model was estimated as a
linear change trajectory with an unstructured covariance ma-
trix for the level 2 random effects.
Second, inter-individual differences in the initial level of
interference with employment (i.e., intercept predictors) were
tested by examining associations with potential demographic,
clinical, and symptom characteristics. Table 1 presents a list of
the proposed predictors that was developed based on a review
of the literature on employment interference in breast cancer
patients [2]. To improve estimation efficiency and construct a
joint model that was parsimonious, an exploratory level 2
analysis was completed in which each potential predictor
was assessed to determine whether it would result in a better
model if it alone were added as a level 2 predictor. Predictors
were examined one-at-a-time to test their association with the
initial level of employment interference (intercept predictor),
as well as whether each predictor was associated with a
change in employment interference over 12 months (slope
predictor). This second effect is often called a “cross-level
interaction” because it tests whether an effect at level 2 (e.g.,
a clinical characteristic measured once) is associated with an
effect at level 1 (i.e., the linear change trajectory of employ-
ment interference over 12 months). For each potential predic-
tor, both the fixed effects at enrollment and the cross-level
interactions were tested with an alpha = .05. Those predictors
that were not significant were dropped from subsequent model
testing. Following these exploratory analyses, all significant
effects at enrollment and significant cross-level interactions
were entered into a joint model.
Missing data for employment interference were accommo-
dated through the use of full information maximum likelihood
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(FIML). Hierarchical linear modeling provides unbiased esti-
mates of change or of the effect of predictors on change even if
some assessments of the outcome are missing or patients drop
out of the study. This accommodation is possible through the
use of FIML [27] with the Expectation-Maximization (EM)
algorithm [27]. This method provides unbiased parameter es-
timates as long as the missingness is ignorable. Even if pa-
tients only provide data at the initial assessment, their data
contribute to the estimation of the intercept (e.g., mean score
at enrollment) and intercept variance. Patients contributed in-
formation to the analysis for as many times as they provided
data. The missing data that did occur was assumed to be miss-
ing at random (one form of “ignorable missingness”) [27].
Results
Sample characteristics
A total of 516 patients were approached and 410 enrolled in
the study (response rate 79.5%). For the current analysis, com-
plete data from 387 women were available. For those women
who declined participation (20.5%), the major reasons for
refusal were: too busy, overwhelmed with their cancer diag-
nosis, or insufficient time available to complete the initial
assessment prior to surgery.
The patients’ demographic, clinical, and symptom charac-
teristics at enrollment are listed in Table 2. On average, pa-
tients were 55 years of age, well educated, within 3 months of
their diagnosis, had a good functional status, and a SCQ score
of 4.2. Most of the women were White (65.6%) and post-
menopausal (64.9%). Forty-one percent of the patients were
married or partnered and 48.1% were working for pay. Over
80% underwent breast conservation surgery. The mean em-
ployment interference score prior to surgery was 3.2 (+3.7;
range 0 to 10).
Individual and mean change in interference
with employment
The first stage of the HLM analysis examined how employ-
ment interference changed from prior to through 12 months
after surgery (Table 3). The intercept represents the estimated
level of interference with employment (i.e., 3.538 on a 0 to 10
scale) at the preoperative assessment. The estimated linear rate
of change in cancer’s interference with employment, for each
additional month, was −0.076 (p < 0.001). Figure 1A displays
the trajectory for cancer’s interference with employment from
the preoperative assessment to 12 months after surgery.
Cancer’s interference with employment decreased over the
course of 12 months. The mean levels of cancer’s interference
with employment scores for the various groups depicted in
Figs. 1 and 2 are estimated or predicted means based on the
HLM analysis.
Inter-individual differences in the trajectories
of interference with employment
The second stage of the HLM analysis evaluated how the
pattern of change over time in cancer’s interference with em-
ployment varied based on specific phenotypic and symptom
characteristics (Table 1). As shown in the final model in
Table 3, the characteristics that predicted inter-individual dif-
ferences in preoperative levels of cancer’s interference with
employment were age, income, axillary lymph node dissec-
tion (ALND) and worst pain intensity score in the breast prior
to surgery. Having a sentinel lymph node biopsy (SLNB) pre-
dicted inter-individual differences in the slope parameter
Table 1 – Potential Predictors of the Intercept (I) and Linear Coefficient
(LC) of the Impact of Cancer or Its Treatment on Employment
Characteristic I LC
Demographic characteristics
Age █
Education
Marital status
Lives alone
Ethnicity (white/nonwhite) █
Annual household income █
Employment status
Hours worked per week
Clinical Characteristics
Body mass index
Karnofsky Performance Status score █ █
Self-Administered Comorbidity Questionnaire score
Gone through menopause █
Time since cancer diagnosis █ █
Stage of disease █
Type of surgery █
Sentinel lymph node biopsy █
Axillary lymph node dissection █
Received neoadjuvant chemotherapy █ █
Reconstruction at the time of surgery █
Symptoms
Depression █
Trait anxiety █
State anxiety █
Fatigue █ █
Energy
Attentional function █
Sleep disturbance █ █
Pain in the affected breast (yes/no) █
Average pain █
Worst pain █
█ = Significant in the exploratory analysis
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Table 2 – Demographic and Clinical Characteristics of the Patients (n = 387)
Characteristic Mean (SD)
Age (years) 55.0 (11.7)
Education (years) 15.7 (2.6)
Self-Administered Comorbidity Questionnaire score 4.2 (2.8)
Karnofsky Performance Status score 93.4 (10.2)
Body mass index (kg/m2) 26.8 (6.1)
% (n)
Ethnicity – White 65.6 (254)
Married/partnered (% yes) 40.8 (158)
Lives alone (% yes) 23.0 (89)
Currently employed (% yes) 48.1 (186)
Hours worked per week 32.6 (15.8)
Annual household income
<$30,000
$30,000 to <$70,000
$70,000 to <$100,000
>$100,000
20.3 (65)
25.6 (18)
16.3 (52)
37.8 (121)
Gone through menopause prior to surgery (% yes) 64.9 (251)
Days since cancer diagnosis (mean (SD)) 70.1 (77.2)
Stage of disease
Stage 0
Stage I
Stage IIa and IIb
Stage IIIa, IIIb, IIIc, and IV
18.6 (72)
38.5 (149)
34.9 (135)
8.0 (31)
Type of surgery
Breast conservation
Mastectomy
80.6 (312)
19.4 (75)
Sentinel lymph node biopsy (% yes) 83.2 (322)
Axillary lymph node dissection (% yes) 37.0 (143)
Underwent reconstruction at the time of surgery (% yes) 22.0 (85)
Received neoadjuvant therapy (% yes) 20.2 (78)
Pain in the affected breast prior to surgery (% yes) 27.1 (105)
Received radiation therapy during the 12 months following surgery (% yes) 71.1 (275)
Received chemotherapy during the 12 months following surgery (% yes) 34.4 (133)
Received hormonal therapy during the 12 months following surgery (% yes) 60.2 (233)
Received complimentary therapy in the 12 months following surgery (% yes) 32.8 (127)
Had breast reconstruction in the 12 months following surgery (% yes) 11.6 (45)
Had re-excision or mastectomy on the affected breast in the six months following surgery (% yes) 30.2 (117)
Mean symptom severity scores at enrollment Mean (SD)
Trait anxiety score 35.2 (8.8)
State anxiety score 41.6 (13.2)
Center of Epidemiologic Studies-Depression Scale score 13.6 (9.6)
Lee Fatigue Scale – fatigue score 3.1 (2.3)
Lee Fatigue Scale – energy score 4.9 (2.5)
Attentional Function Index score 6.6 (1.9)
General Sleep Disturbance Scale score 48.1 (21.3)
Average pain intensity score in the breast prior to surgery 0.6 (1.3)
Worst pain intensity score in the breast prior to surgery 0.9 (1.9)
Degree that illness or treatment interfered with your employment 3.2 (3.7)
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Fig. 1 Trajectory of cancer’s interference with employment (A) and influence of age (B), income (C), axillary lymph node dissection (D), and pain (E) on
inter-individual differences in the intercept parameters for cancer’s interference with employment
Table 3 – Unconditional and Joint Conditional Multilevel Linear Regression Models for Interference with Employment
Variable Coefficient (SE)
Unconditional Model Final Model
Fixed effects
Intercept 3.538 (.183)+ 3.213 (.177)+
Time (linear rate of change) −0.076 (.013)+ −0.072 (.015)+
Intercept
Age −0.098 (.015)+
Income −0.194 (.045)+
Axillary lymph node dissection 1.283 (.331)+
Sentinel lymph node biopsy 0.529 (.459)
Worst pain score in the breast prior to surgery 0.163 (.089)
Sleep disturbance score 0.018 (.008)*
Linear
Sentinel lymph node biopsy x time −0.109 (.038)*
Sleep disturbance score x time −0.002 (.001)+
Time varying covariates
Chemotherapy 0.460 (.130)+
Complementary or alternative therapy 0.434 (.147)*
Re-excision or mastectomy of the affected breast 0.620 (.195)*
*p < .05, +p < .001
Abbreviations: SE = standard error
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estimates for cancer’s interference with employment. Sleep
disturbance predicted inter-individual differences in both the
intercept and slope parameter estimates for cancer’s interfer-
ence with employment.
To illustrate the effects of the above predictors on patients’
initial levels and trajectories of cancer’s interference with em-
ployment, Fig. 1B, C, D, and E display the adjusted change
curves for cancer’s interference with employment that were
estimated based on differences in age (i.e., younger/older age
calculated based on one SD above and below the mean age),
levels of income prior to surgery (i.e., lower/higher levels of
income calculated based on one SD above and below the
mean income level), occurrence of an ALND (yes or no),
and pain (i.e., lower/higher levels of worst pain calculated
based on one SD above and below the mean worst pain
scores), respectively. Fig. 2A and B display the adjusted
change curves for cancer’s interference with employment that
were estimated based on differences in occurrence of a SLNB
(yes or no) and levels of sleep disturbance (i.e., lower/higher
levels of sleep disturbance calculated based on one SD above
and below the mean GSDS score).
In terms of the time varying covariates, of the six that were
evaluated, only three remained significant in the final model
(Table 3). Over the 12month period of the study, the receipt of
chemotherapy, the use of complementary and alternative ther-
apies, and the occurrence of re-excision or mastectomy, at
some time during the 12 months, were associated with greater
interference with employment.
Discussion
This study is the first to use HLM to examine inter-individual
variability in the trajectories of cancer’s interference with em-
ployment from prior to through 12 months after breast cancer
surgery and to investigate whether demographic, clinical, and
symptom characteristics predicted preoperative levels and
changes in the trajectories of cancer’s interference with em-
ployment. Consistent with previous reports [28, 29], cancer’s
interference with employment decreased slowly over time.
While 40.8% of patients in this study reported that they were
not working for pay prior to surgery, we cannot determine
whether unemployment at this point in the disease trajectory
was attributable to the cancer diagnosis or previous (i.e.,
21.7% of the patients had neoadjuvant chemotherapy) or fu-
ture treatments. However, we overcame the issue of
attributability by directly asking patients to rate their cancer’s
interference with employment over 12 months instead of
assessing self-reported sick leave or return to work.
Age, income, ALND, and pain intensity were associated
with inter-individual differences in cancer’s interference with
employment at enrollment. In this study, younger age and
lower income were associated with higher levels of employ-
ment interference. Consistent with previous reports [10,
30–32], people with a lower income are more likely to report
unemployment or employment issues after cancer. In contrast,
the relationship between age and employment changes, in
women with breast cancer, is less clear with one study finding
that older age limited or delayed return to work [33] and an-
other study showing that younger age was associated with
increased sick leave [34]. One potential explanation for our
finding is that women who are younger may have higher ex-
pectations about being able to return to work and a stronger
desire to progress in their careers [35]. To examine this rela-
tionship further, future studies need to incorporate both
patient-reported employment interference and objective (e.g.,
absenteeism, decreases in work hours) measures. An addition-
al consideration, particularly for women, is an evaluation of
work productivity even if they are not in the workforce (i.e.,
unpaid productivity).
In this study, while ALND was an intercept predictor,
SLNB was a predictor of the slope. Compared to having a
Fig. 2 Influence of sentinel lymph node biopsy (A) and sleep disturbance
(B) on inter-individual differences in the slope parameters for cancer’s
interference with employment
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SLNB (Fig. 2A), the receipt of an ALND has a relatively
larger impact on patients’ interference with employment
(Fig. 1D). This finding is expected because an ALND is asso-
ciated with more severe adverse effects (e.g., upper limb mor-
bidity, immobility associated with axillary pain and arm swell-
ing [28, 29, 36]) which may limit patients’ ability to return to
normal activities and employment [29]. The relationship be-
tween having a SLNB and employment interference is less
clear (Fig. 2A). The finding that not having a SLNB was
associated with an increasing trajectory of employment inter-
ference may be partially explained by the fact that 5.4% (21/
387) of the women who did not have a SLNB did have an
ALND at the time of surgery.
Consistent with findings from a systematic literature re-
view [2], in the exploratory analysis, a number of symptoms
including depression, anxiety, fatigue, cognitive impairment,
sleep disturbance and pain (Table 1) were associated with
inter-individual differences in cancer’ interference with em-
ployment at enrollment. However, only pain and sleep distur-
bance were retained in the final model. Preoperative breast
pain may be associated with higher levels of employment
interference because in our previous work we found that
women with this type of pain reported higher levels of depres-
sion [16], anxiety [16], sleep disturbance [16], and disability
[37]. Regarding sleep disturbance (Fig. 2B), higher preopera-
tive levels of sleep disturbance were associated with higher
levels of employment interference that decreased slowly over
time. In contrast, lower levels of sleep disturbance at enroll-
ment, were associated with slight increases in employment
interference over time. The factors that influence the relation-
ships between sleep disturbance (e.g., use of effective sleep
hygiene strategies [38], changes in anxiety [39]) and employ-
ment interference warrant additional investigation.
Receipt of chemotherapy, use of complementary or alter-
native therapies, and re-excision ormastectomy of the affected
breast after the initial surgery were the time varying covariates
that were associated with higher levels of employment inter-
ference. Plausible explanations for the positive associations
between the receipt of chemotherapy, or re-excision or mas-
tectomy and employment interference include: work interrup-
tions to receive chemotherapy, management of treatment re-
lated side effects, and the time required to recover from the
additional surgical procedure(s). It is possible that women
who used complementary or alternative therapies had more
severe side effects [40, 41] that required them to take time
off from work. These findings suggest that clinicians need to
perform ongoing assessments to determine the impact of
breast cancer treatments on employment interference and ini-
tiate appropriate referrals.
One of this study’s limitations is that objective measures of
employment interference (e.g., returning to work, reduced
work hours, sick leave) were not collected. Instead, this study
focused on patients’ assessment of cancer’s interference with
employment which allowed us to assess inter-individual var-
iability in this outcome. In addition, information on the pa-
tients’ occupations which could influence their ability to re-
turn to work was not collected. Finally, given differences
across countries in terms of insurance coverage and sick leave
benefits, our findings may not generalize to other countries
with more restrictive or liberal benefits.
In terms of clinical implications, evidence exists that mul-
tidisciplinary interventions, that include physical, psycho-ed-
ucational, and vocational components can assist cancer pa-
tients to return to work [42]. Therefore, clinicians need to
assess for employment interference and engage in discussions
regarding plans for returning to work and alternative careers
and opportunities; make referrals to social services; and pro-
vide practical information (e.g., legal rights) [43]. In addition,
the use of effective symptom management interventions, par-
ticularly for pain and sleep disturbance, may decrease the im-
pact of cancer and its treatment on employment interference.
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